Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neurosense Therapeutics Ltd. (NRSN) Stock Price & Analysis

NRSN Stock Chart & Stats

$1.99-$0.14(-6.57%)
At close: 4:00 PM EDT
$2.5$5$7.5$103 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$1.99 - $2.22
52-Week Range
$1.99 - $25.40
Previous Close
$2.13
Volume
86.30K
Average Volume (3M)
24.45K
Market Cap
$3.77M
Enterprise Value
$24.53M
Total Cash (Recent Filing)
$166.00K
Total Debt (Recent Filing)
$170.00K
Price to Earnings (P/E)
―
Beta
1.15
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory Progress

Advancing from supportive Phase 2b evidence toward a pivotal Phase 3 trial and a planned Canadian filing materially strengthens PrimeC’s development pathway. These milestones could expand regulatory and commercial options if the company executes successfully and confirms efficacy.

Potential Early Commercialization

The collaboration could create an early revenue channel before traditional approval while maintaining the broader clinical program. If legal, regulatory, and operational milestones are met, this may improve patient access, validate demand, and diversify the company’s funding model.

Expanding Intellectual Property

Extending PrimeC’s intellectual-property strategy beyond ALS could broaden the addressable opportunity and support future partnering or non-dilutive funding discussions. Protection in additional neurological indications may also strengthen the platform’s strategic value over time.

Bears Say

Pre-revenue Operating Losses

The absence of commercial revenue leaves the company dependent on financing and future clinical success to support operations. Persistent, substantial losses without offsetting sales increase the risk that commercialization takes longer or requires additional capital before profitability is reached.

Heavy Cash Burn And Weak Balance Sheet

Ongoing cash outflows and negative equity materially constrain financial flexibility despite minimal debt. The shrinking asset base and continued burn make external funding important for clinical execution, increasing dilution or funding-delay risk if capital is not secured.

Nasdaq Listing And Funding Execution Risk

The unresolved listing deficiency can complicate access to public capital and increase execution pressure while the company funds its pivotal trial. Delays in financing or failure to obtain an exception could weaken operating flexibility and hinder PrimeC’s development timetable.

Neurosense Therapeutics Ltd. News

NRSN FAQ

What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $1.99 and its highest was $25.40 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $3.77M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Sep 25, 2026. The company reported -$2.06 earnings per share for the quarter, beating the consensus estimate of -$3.9 by $1.84.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 1,896,902 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$2.06 in its last earnings report, beating expectations of -$3.9. Following the earnings report the stock price went down -26.619%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Hedge funds hold Neurosense Therapeutics Ltd. shares: the largest hedge-fund position in Neurosense Therapeutics Ltd. is 62,363,456 shares, and hedge funds decreased their holdings by 979.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology